Denmark-based pharma company Zealand Pharma has added Dr Martin Nicklasson and Catherine Moukheibir the company’s board of directors in the role of observers.
The announcement comes just days after the pharma company revealed Britt Meelby Jensen as its new CEO.
Nicklasson has held various executive VP positions at AstraZeneca and was president and CEO of BioVitrum and Swedish Orphan Biovitrum. He is also chairman of the board of Basilea, Orexo and Farma Holding.
Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking. She is currently a non-executive board member of Creabilis and Ablynx.
Daniel Ellens, chairman of the Zealand board of directors, said: “They provide important and broad-based experience from public life science companies and are important additions to the competences on the board as we prepare for the next steps in Zealand’s growth strategy as a maturing biotech company.”